ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "FK506"

  • 2022 American Transplant Congress

    Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation

    N. Fujiyama1, M. Saito2, R. Yamamoto2, R. Sagehashi2, T. Saito2, Y. Aoyama2, K. Numakura2, T. Habuchi2, S. Satoh1

    1Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan, 2Department of Urology, Akita University Graduate School of Medicine, Akita, Japan

    *Purpose: In this study, we aimed to identify the risk factors contributing to the development of donor-specific anti-HLA antibody (DSA) during long-term follow-up of patients…
  • 2022 American Transplant Congress

    The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients

    A. van Rijn, S. Meziyerh, D. van der Helm, T. van Gelder, A. Kroes, J. de Fijter, D. Moes, J. Rotmans, A. de Vries, M. Feltkamp

    Leiden University Medical Center, Leiden, Netherlands

    *Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…
  • 2022 American Transplant Congress

    Detection of Early Graft Injury After Liver Transplantation with Blood-Bile Ratio of Tacrolimus: The TUBE Trial

    M. M. Pascale1, G. Bianco1, L. Ferri1, F. Giovinazzo1, A. Liguori2, G. Marrone2, A. Grieco2, S. Agnes1

    1General Surgery and Liver Transplant Unit, Fondazione IRCSS - Policlinico "A. Gemelli", Roma, Italy, 2Transplant Hepatology Unit, Fondazione IRCSS - Policlinico "A. Gemelli", Roma, Italy

    *Purpose: The aim of the“Tacrolimus in Bile”(TUBE)Trial is the creation of a laboratory parameter for the early detection of hepatic injury after liver transplant.*Methods: TUBE…
  • 2022 American Transplant Congress

    Effect of Schisandra Sphenanthera Extract on Pharmacokinetics of Tacrolimus in Pediatric Renal Transplant Recipients

    J. Jiang1, H. Zhang1, X. Su1, S. Wu1, Y. Chen2, W. Chen2, J. Li2, C. Wu2, L. Yang2, L. Liu2, C. Wang2

    1Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    *Purpose: Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent in adult renal transplant recipients, while its effect in pediatric recipients remains unclear. The…
  • 2022 American Transplant Congress

    Effect of Dual Inhibition of DPP4 and SGLT2 on Tacrolimus-Induced Diabetes Mellitus and Nephrotoxicity in Rat Model

    E. Ko, Y. Shin, C. Seung, S. Lim, B. Chung, C. Yang

    Seoul St.Mary's Hospital, Seoul, Korea, Republic of

    *Purpose: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) are popular anti-diabetic drugs in type II diabetes mellitus (DM), but their use in…
  • 2022 American Transplant Congress

    Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients

    R. A. Arora, C. Kane, K. Lang, M. Kapugi, C. D'Agostino, K. Cunningham, S. H. Park

    Northwestern Memorial Hospital, Chicago, IL

    *Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…
  • 2022 American Transplant Congress

    Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure

    A. Yishak1, S. Ledan2, S. Mukherjee3, C. Chen2, A. Ayoola2, T. Kim2, A. Olenik2, K. Mullican2, A. Henje2, N. Lorence2, L. Beckman2

    1MAPMG, Mc Lean, VA, 2Kaiser Permanente, Silver Spring, MD, 3MAPMG, Rockville, MA

    *Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…
  • 2021 American Transplant Congress

    Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients

    A. Demirag1, P. L. Lobo2, J. Oberholzer1, A. Kumar2, B. Rawashdeh1, S. L. Lennon1, H. N. Guvener Demirag1, A. Doyle2, J. Geystone3, K. L. Brayman1

    1Transplantation, University of Virginia Medical Center, Charlottesville, VA, 2Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, 3Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA

    *Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
  • 2021 American Transplant Congress

    De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience

    N. Singh1, T. Le1, M. S. Naseer1, S. Asmil1, A. Palermini1, A. Qamar1, R. Chand1, S. Tandukar1, D. Aultman2, H. Shokouh-Amiri2, G. Zibari2

    1Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, 2Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA

    *Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
  • 2021 American Transplant Congress

    The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients

    T. Carcella, F. Bartlett, N. Patel, V. Rohan, D. Taber

    Medical University of South Carolina, Charleston, SC

    *Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences